{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:40:46Z","timestamp":1770226846278,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study is to evaluate semaphorin 3A levels in patients with systemic lupus erythematosus (SLE) with and without renal involvement and secondary antiphospholipid antibody syndrome (APS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with SLE were grouped according to the presence of secondary APS or renal involvement. The control group consisted of age-matched, nonsmoking, healthy volunteers. Semaphorin 3A levels were compared among groups. All patients with SLE were regrouped according to the presence of thrombotic events, miscarriages, and proteinuria, and semaphorin 3A levels were investigated. Finally, semaphorin 3A levels of all patients with SLE as a single group were compared to those of the control patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean semaphorin 3A values were 16.16 \u00b1 2.84 ng\/mL in the control group, 9.05\u2005\u00b1\u20055.65 ng\/mL in patients with SLE without nephritis and APS, 11.28\u2005\u00b1\u20055.23 ng\/mL in the SLE with APS group, and 8.53\u2005\u00b1\u20055.11 ng\/mL in the lupus nephritis group. When all 3 patient groups were examined as a single group, the mean semaphorin 3A value was significantly lower than that of the control group. Semaphorin 3A was reduced in patients with SLE with thromboembolism and\/or history of miscarriage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Semaphorin 3A levels were lower in all patient groups compared to the control group. Moreover, the reduced semaphorin 3A levels in patients with a history of thromboembolism and\/or miscarriage suggest that semaphorin 3A may play an important role in the pathogenesis of vasculopathy.<\/jats:p><\/jats:sec>","DOI":"10.1093\/labmed\/lmab096","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T21:36:23Z","timestamp":1632432983000},"page":"285-289","source":"Crossref","is-referenced-by-count":2,"title":["Semaphorin 3A Levels in Lupus with and without Secondary Antiphospholipid Antibody Syndrome and Renal Involvement"],"prefix":"10.1093","volume":"53","author":[{"given":"G\u00f6zde Sevgi","family":"Kart Bayram","sequence":"first","affiliation":[{"name":"Ankara City Hospital, Internal Medicine , \u00dcniversiteler Mahallesi, Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulsamet","family":"Erden","sequence":"additional","affiliation":[{"name":"Ankara City Hospital, Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do\u011fan","family":"Bayram","sequence":"additional","affiliation":[{"name":"Ankara City Hospital, Internal Medicine , \u00dcniversiteler Mahallesi, Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahar","family":"\u00d6zdemir","sequence":"additional","affiliation":[{"name":"Ankara City Hospital, Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zlem","family":"Karaka\u015f","sequence":"additional","affiliation":[{"name":"Ankara City Hospital, Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Apayd\u0131n","sequence":"additional","affiliation":[{"name":"Ankara City Hospital, Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orta\u00e7","family":"Ate\u015f","sequence":"additional","affiliation":[{"name":"Ankara City Hospital, Biochemistry , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar Can","family":"G\u00fcven","sequence":"additional","affiliation":[{"name":"Ankara City Hospital, Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berkan","family":"Arma\u011fan","sequence":"additional","affiliation":[{"name":"Ankara City Hospital, Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevser","family":"G\u00f6k","sequence":"additional","affiliation":[{"name":"Ankara City Hospital, Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y\u00fcksel","family":"Mara\u015f","sequence":"additional","affiliation":[{"name":"Ankara City Hospital, Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Omma","sequence":"additional","affiliation":[{"name":"TC Saglik Bakanligi Ankara Numune Egitim ve Arastirma Hastanesi , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"K\u00fc\u00e7\u00fck\u015fahin","sequence":"additional","affiliation":[{"name":"Ankara Yildirim Beyazit University, Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan","family":"Top\u00e7uo\u011flu","sequence":"additional","affiliation":[{"name":"Ankara Numune Education and Research Hospital, Biochemistry Department , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015e\u00fckran","family":"Erten","sequence":"additional","affiliation":[{"name":"Ankara Yildirim Beyazit University, Rheumatology , Ankara , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,11,20]]},"reference":[{"issue":"1","key":"2023020400335326700_CIT0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autrev.2010.09.007","article-title":"Updating on the pathogenesis of systemic lupus erythematosus","volume":"10","author":"Gualtierotti","year":"2010","journal-title":"Autoimmun Rev."},{"issue":"1\u20132","key":"2023020400335326700_CIT0002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.20452\/pamw.306","article-title":"Vasculopathy and vasculitis in systemic lupus erythematosus","volume":"118","author":"Cie\u015blik","year":"2008","journal-title":"Pol Arch Med Wewn."},{"key":"2023020400335326700_CIT0003","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fimmu.2019.00449","article-title":"Complement in the pathophysiology of the antiphospholipid syndrome","volume":"10","author":"Chaturvedi","year":"2019","journal-title":"Front Immunol."},{"issue":"5707","key":"2023020400335326700_CIT0004","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1126\/science.1105416","article-title":"Semaphorin 3E and plexin-D1 control vascular pattern independently of neurophilins","volume":"307","author":"Gu","year":"2005","journal-title":"Science."},{"issue":"9","key":"2023020400335326700_CIT0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrn3302","article-title":"Getting neural circuits into shape with semaphorins","volume":"13","author":"Pasterkamp","year":"2012","journal-title":"Nat Rev Neurosci."},{"issue":"2","key":"2023020400335326700_CIT0006","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/cmi.2009.111","article-title":"Regulation of immune cell responses by semaphorins and their receptors","volume":"7","author":"Takamatsu","year":"2010","journal-title":"Cell Mol Immunol."},{"issue":"36","key":"2023020400335326700_CIT0007","doi-asserted-by":"crossref","first-page":"26294","DOI":"10.1074\/jbc.M609711200","article-title":"Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis","volume":"282","author":"Guttmann-Raviv","year":"2007","journal-title":"J Biol Chem."},{"issue":"1","key":"2023020400335326700_CIT0008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrrheum.2017.201","article-title":"The role of semaphorins in immune responses and autoimmune rheumatic diseases","volume":"14","author":"Nishide","year":"2018","journal-title":"Nat Rev Rheumatol."},{"issue":"8","key":"2023020400335326700_CIT0009","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"1","key":"2023020400335326700_CIT0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/BOR.0000000000000240","article-title":"Recognition and management of antiphospholipid syndrome","volume":"28","author":"Gerosa","year":"2016","journal-title":"Curr Opin Rheumatol."},{"key":"2023020400335326700_CIT0011","article-title":"Could urinary kidney injury molecule-1 be a good marker in subclinical acute kidney injury in mild to moderate COVID-19 infection?","author":"Yasar","year":"2021","journal-title":"Int Urol Nephrol."},{"issue":"7","key":"2023020400335326700_CIT0012","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/ni.1885","article-title":"Semaphorins guide the entry of dendritic cells into the lymphatics by activating myosin II","volume":"11","author":"Takamatsu","year":"2010","journal-title":"Nat Immunol."},{"issue":"3","key":"2023020400335326700_CIT0013","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/intimm\/dxn006","article-title":"Plexin-A4 negatively regulates T lymphocyte responses","volume":"20","author":"Yamamoto","year":"2008","journal-title":"Int Immunol."},{"issue":"1\u22602","key":"2023020400335326700_CIT0014","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/08820139.2019.1649280","article-title":"Decreased expression of semaphorin 3A and semaphorin 7A levels and its association with systemic lupus erythematosus","volume":"49","author":"Wang","year":"2020","journal-title":"Immunol Invest."},{"issue":"3","key":"2023020400335326700_CIT0015","doi-asserted-by":"crossref","first-page":"R146","DOI":"10.1186\/ar3881","article-title":"Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus","volume":"14","author":"Vadasz","year":"2012","journal-title":"Arthritis Res Ther."},{"issue":"5","key":"2023020400335326700_CIT0016","first-page":"370","article-title":"Expression and clinical significance of semaphorin 3A in serum and mononuclear cells in patients with systemic lupus erythematosus","volume":"97","author":"Gao","year":"2017","journal-title":"Zhonghua Yi Xue Za Zhi."},{"issue":"6947","key":"2023020400335326700_CIT0017","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature01784","article-title":"Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function","volume":"424","author":"Serini","year":"2003","journal-title":"Nature."},{"issue":"11","key":"2023020400335326700_CIT0018","first-page":"3356","article-title":"Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models","volume":"119","author":"Maione","year":"2009","journal-title":"J Clin Invest."},{"issue":"12","key":"2023020400335326700_CIT0019","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00109-014-1209-3","article-title":"Urinary semaphorin 3A correlates with diabetic proteinuria and mediates diabetic nephropathy and associated inflammation in mice","volume":"92","author":"Mohamed","year":"2014","journal-title":"J Mol Med (Berl)."},{"issue":"3","key":"2023020400335326700_CIT0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40620-014-0097-5","article-title":"Increased urine semaphorin-3A is associated with renal damage in hypertensive patients with chronic kidney disease: a nested case-control study","volume":"28","author":"Viazzi","year":"2015","journal-title":"J Nephrol."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/3\/285\/49087983\/lmab096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/3\/285\/49087983\/lmab096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T19:19:15Z","timestamp":1725823155000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/53\/3\/285\/6432481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,20]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,11,20]]},"published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmab096","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,11,20]]}}}